Positive Clinical Trial Results Spur American Gene Technologies to Launch Addimmune, a Company with One Focus: Cure HIV

When Jeff Galvin founded American Gene Technologies in 2008, he envisioned a future where gene therapy could be used to write disease out of the genetic code. Today, on June 9, 2023, that future just got a lot closer with three major announcements:

• The company’s HIV gene therapy, AGT103-T, has yielded encouraging data through two separate clinical studies. The trajectory projected by these data sets puts the program on track to accomplish its goal of functionally curing patients.
• To propel..